Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species

Julia E. Gerson, Diana L. Castillo-Carranza, Rakez Kayed

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations

Abstract

Neurodegenerative disease is one of the greatest health concerns today and with no effective treatment in sight, it is crucial that researchers find a safe and successful therapeutic. While neurofibrillary tangles are considered the primary tauopathy hallmark, more evidence continues to come to light to suggest that soluble, intermediate tau aggregates - tau oligomers - are the most toxic species in disease. These intermediate tau species may also be responsible for the spread of pathology, suggesting that oligomeric tau may be the best therapeutic target. Here, we summarize results for the modulation of tau by molecular chaperones, small molecules and aggregation inhibitors, post-translational modifications, immunotherapy, other techniques, and future directions. (Figure Presented).

Original languageEnglish (US)
Pages (from-to)752-769
Number of pages18
JournalACS chemical neuroscience
Volume5
Issue number9
DOIs
StatePublished - Sep 17 2014

Keywords

  • Immunotherapy
  • Molecular chaperones
  • Oligomers
  • Small molecules

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint

Dive into the research topics of 'Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species'. Together they form a unique fingerprint.

Cite this